Knowledge, Perception, and Use of Cannabis Therapy in Patients with Inflammatory Bowel Disease.

IF 0.4 4区医学 Q4 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH

Puerto Rico Health Sciences Journal Pub Date : 2021-09-01

Luis A Muñiz-Camacho, Frances I Negrón-Quintana, Luis A Ramos-Burgos, Jorge J Cruz-Cruz, Esther A Torres

{"title":"Knowledge, Perception, and Use of Cannabis Therapy in Patients with Inflammatory Bowel Disease.","authors":"Luis A Muñiz-Camacho, Frances I Negrón-Quintana, Luis A Ramos-Burgos, Jorge J Cruz-Cruz, Esther A Torres","doi":"","DOIUrl":null,"url":null,"abstract":"Objective: In 2017, the government of Puerto Rico legalized medical cannabis for several conditions including Crohn's disease (CD). There is little information about cannabis use in this population. This study aimed to develop a demographic characterization and evaluate patient perception on cannabis use for Inflammatory Bowel Disease (IBD) at the University of Puerto Rico Center for Inflammatory Bowel Diseases.Methods: One hundred patients of ages 21 or older with a confirmed diagnosis of IBD were recruited to complete a voluntary anonymous questionnaire.Results: 27% of the surveyed participants reported use of cannabis. Of these, 39% reported moderate knowledge and 53% reported little to no knowledge of medical cannabis. The majority did not discuss cannabis use with their physician (78%), and most saw improvement of their symptoms (68%).Conclusion: Cannabis is frequently considered by patients as a treatment option for IBD but most have limited knowledge about its use. The low number of patients that discuss cannabis use with their physician suggests the need for physician awareness of unreported use. It should also lead to the development of strategies for patient orientation regarding the uses, properties, and expectations of cannabis as a therapy.","PeriodicalId":54529,"journal":{"name":"Puerto Rico Health Sciences Journal","volume":"40 3","pages":"110-114"},"PeriodicalIF":0.4000,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Puerto Rico Health Sciences Journal","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: In 2017, the government of Puerto Rico legalized medical cannabis for several conditions including Crohn's disease (CD). There is little information about cannabis use in this population. This study aimed to develop a demographic characterization and evaluate patient perception on cannabis use for Inflammatory Bowel Disease (IBD) at the University of Puerto Rico Center for Inflammatory Bowel Diseases.

Methods: One hundred patients of ages 21 or older with a confirmed diagnosis of IBD were recruited to complete a voluntary anonymous questionnaire.

Results: 27% of the surveyed participants reported use of cannabis. Of these, 39% reported moderate knowledge and 53% reported little to no knowledge of medical cannabis. The majority did not discuss cannabis use with their physician (78%), and most saw improvement of their symptoms (68%).

Conclusion: Cannabis is frequently considered by patients as a treatment option for IBD but most have limited knowledge about its use. The low number of patients that discuss cannabis use with their physician suggests the need for physician awareness of unreported use. It should also lead to the development of strategies for patient orientation regarding the uses, properties, and expectations of cannabis as a therapy.

本刊更多论文

炎症性肠病患者大麻治疗的知识、感知和使用。

目的:2017年，波多黎各政府将包括克罗恩病(CD)在内的几种疾病的医用大麻合法化。关于这一人群使用大麻的信息很少。本研究旨在发展人口统计学特征，并评估波多黎各大学炎症性肠病中心患者对使用大麻治疗炎症性肠病(IBD)的看法。方法:招募100名年龄在21岁或以上确诊为IBD的患者完成一份自愿匿名问卷。结果:27%的调查参与者报告使用大麻。其中，39%的人表示对医用大麻有中等程度的了解，53%的人表示对医用大麻知之甚少或一无所知。大多数人没有与医生讨论大麻的使用(78%)，大多数人的症状有所改善(68%)。结论:大麻经常被患者视为IBD的一种治疗选择，但大多数人对其使用的了解有限。与医生讨论大麻使用情况的患者人数很少，这表明医生有必要了解未报告的使用情况。它还应导致制定关于大麻作为一种疗法的用途、特性和期望的患者导向战略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Puerto Rico Health Sciences Journal PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-

CiteScore

0.60

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： The Puerto Rico Health Sciences Journal (PRHSJ) is the scientific journal of the University of Puerto Rico Medical Sciences Campus. It was founded in 1982 as a vehicle for the publication of reports on scientific research conducted in-campus, Puerto Rico and abroad. All published work is original and peer-reviewed. The PRHSJ is included in PubMed/Medline, SCOPUS, Latindex, EBSCO, SHERPA/RoMEO, Science Citation Index Expanded (SciSearch®) and Journal Citation Reports/Science Edition. All papers are published both online and in hard copy. From its beginning, the PRHSJ is being published regularly four times a year. The scope of the journal includes a range of medical, dental, public health, pharmaceutical and biosocial sciences research. The journal publishes full-length articles, brief reports, special articles, reviews, editorials, case reports, clinical images, and letters arising from published material.